Gladman Dafna D, Poulin Yves, Adams Karen, Bourcier Marc, Barac Snezana, Barber Kirk, Chandran Vinod, Dutz Jan, Flanagan Cathy, Gooderham Melinda J, Gulliver Wayne P, Ho Vincent C, Hong Chih-Ho, Karsh Jacob, Khraishi Majed M, Lynde Charles W, Papp Kim A, Rahman Proton, Rohekar Sherry, Rosen Cheryl F, Russell Anthony S, Vender Ronald B, Yeung Jensen, Ziouzina Olga, Zummer Michel
From the University of Toronto, Toronto, Ontario; Université Laval, Quebec, Quebec; Queen's University, Kingston; University of Ottawa, Ottawa; Western University, London; Dermatrials Research, Inc., Hamilton, Ontario; Université de Montréal, Montreal; Université de Sherbrooke, Sherbrooke, Quebec; The Winnipeg Clinic, Winnipeg, Manitoba; University of Calgary, Calgary; University of Alberta, Edmonton, Alberta; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto; Y. Poulin, MD, Université Laval; K. Adams, MD, Université Laval; M. Bourcier, MD, Université de Sherbrooke; S. Barac, MD, The Winnipeg Clinic; K. Barber, MD, University of Calgary; V. Chandran, MBBS, MD, DM, PhD, University of Toronto; J. Dutz, MD, University of British Columbia; C. Flanagan, MD, University of British Columbia; M.J. Gooderham, MD, Queen's University; W.P. Gulliver, MD, Memorial University of Newfoundland; V.C. Ho, MD, University of British Columbia; C.H. Hong, MD, University of British Columbia; J. Karsh, MD, University of Ottawa; M.M. Khraishi, MBBCH, Memorial University of Newfoundland; C.W. Lynde, MD, University of Toronto; K.A. Papp, MD, PhD, University of Toronto; P. Rahman, MD, Memorial University of Newfoundland; S. Rohekar, MD, Western University; C.F. Rosen, MD, University of Toronto; A.S. Russell, MD, University of Alberta; R.B. Vender, MD, Dermatrials Research, Inc.; J. Yeung, MD, University of Toronto; O. Ziouzina, MD, University of Calgary; M. Zummer, MD, Université de Montréal.
J Rheumatol. 2017 Apr;44(4):519-534. doi: 10.3899/jrheum.161473.
To develop preliminary treat-to-target (T2T) recommendations for psoriasis and psoriatic arthritis (PsA) for Canadian daily practice.
A task force composed of expert Canadian dermatologists and rheumatologists performed a needs assessment among Canadian clinicians treating these diseases as well as an extensive literature search on the outcome measures used in clinical trials and practice.
Based on results from the needs assessment and literature search, the task force established 5 overarching principles and developed 8 preliminary T2T recommendations.
The proposed recommendations should improve management of psoriasis and PsA in Canadian daily practice. However, these recommendations must be further validated in a real-world observational study to ensure that their use leads to better longterm outcomes.
为加拿大日常临床实践制定银屑病和银屑病关节炎(PsA)的初步治疗达标(T2T)建议。
一个由加拿大皮肤科专家和风湿病专家组成的特别工作组对治疗这些疾病的加拿大临床医生进行了需求评估,并对临床试验和实践中使用的结局指标进行了广泛的文献检索。
基于需求评估和文献检索的结果,特别工作组确立了5项总体原则,并制定了8项初步的T2T建议。
所提出的建议应能改善加拿大日常临床实践中银屑病和PsA的管理。然而,这些建议必须在一项真实世界观察性研究中进一步验证,以确保其使用能带来更好的长期结局。